Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05042076 · ClinicalTrials.gov registry record · Phase 1
BK With VST for Kidney Transplant Patients
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05042076 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 3 participants.
The verdict
NCT05042076, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study measures the safety, feasibility, and efficacy of viral-specific T cells (VST) against BK Virus (BKV) in adult kidney transplant recipients. Participants are expected to be on study for 52 weeks.
Interventions
- DRUG BK-specific T cells from Donor Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2024-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05042076
The ClinicalTrials.gov registry entry for NCT05042076 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BK-specific T cells from Donor Lymphocytes is the first listed.
NCT05042076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05042076 about?
NCT05042076 is a clinical study titled "BK With VST for Kidney Transplant Patients". This study measures the safety, feasibility, and efficacy of viral-specific T cells (VST) against BK Virus (BKV) in adult kidney transplant recipients. Participants are expected to be on study for 52 weeks.
What is the current status of trial NCT05042076?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-12-16. Estimated completion is 2024-05-14.
What interventions are being tested in trial NCT05042076?
The interventions under investigation include: BK-specific T cells from Donor Lymphocytes (DRUG).
Who is sponsoring clinical trial NCT05042076?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.